Activation and Inhibition of Human Matrix Metalloproteinase-9 (MMP9) by HOCl, Myeloperoxidase and Chloramines

Matrix metalloproteinase-9 (MMP9, gelatinase B) plays a key role in the degradation of extracellular-matrix (ECM) proteins in both normal physiology and multiple pathologies, including those linked with inflammation. MMP9 is excreted as an inactive proform (proMMP9) by multiple cells, and particular...

Full description

Saved in:
Bibliographic Details
Main Authors: Yihe Wang (Author), Christine Y. Chuang (Author), Clare L. Hawkins (Author), Michael J. Davies (Author)
Format: Book
Published: MDPI AG, 2022-08-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_5d7fc843b0ab43f08fde4b35b0ad0ea9
042 |a dc 
100 1 0 |a Yihe Wang  |e author 
700 1 0 |a Christine Y. Chuang  |e author 
700 1 0 |a Clare L. Hawkins  |e author 
700 1 0 |a Michael J. Davies  |e author 
245 0 0 |a Activation and Inhibition of Human Matrix Metalloproteinase-9 (MMP9) by HOCl, Myeloperoxidase and Chloramines 
260 |b MDPI AG,   |c 2022-08-01T00:00:00Z. 
500 |a 10.3390/antiox11081616 
500 |a 2076-3921 
520 |a Matrix metalloproteinase-9 (MMP9, gelatinase B) plays a key role in the degradation of extracellular-matrix (ECM) proteins in both normal physiology and multiple pathologies, including those linked with inflammation. MMP9 is excreted as an inactive proform (proMMP9) by multiple cells, and particularly neutrophils. The proenzyme undergoes subsequent processing to active forms, either enzymatically (e.g., via plasmin and stromelysin-1/MMP3), or via the oxidation of a cysteine residue in the prodomain (the "cysteine-switch"). Activated leukocytes, including neutrophils, generate O<sub>2</sub><sup>−</sup> and H<sub>2</sub>O<sub>2</sub> and release myeloperoxidase (MPO), which catalyzes hypochlorous acid (HOCl) formation. Here, we examine the reactivity of HOCl and a range of low-molecular-mass and protein chloramines with the pro- and activated forms of MMP9. HOCl and an enzymatic MPO/H<sub>2</sub>O<sub>2</sub>/Cl<sup>−</sup> system were able to generate active MMP9, as determined by fluorescence-activity assays and gel zymography. The inactivation of active MMP9 also occurred at high HOCl concentrations. Low (nM-low μM) concentrations of chloramines formed by the reaction of HOCl with amino acids (taurine, lysine, histidine), serum albumin, ECM proteins (laminin and fibronectin) and basement membrane extracts (but not HEPES chloramines) also activate proMMP9. This activation is diminished by the competitive HOCl-reactive species, methionine. These data indicate that HOCl-mediated oxidation and MMP-mediated ECM degradation are synergistic and interdependent. As previous studies have shown that modified ECM proteins can also stimulate the cellular expression of MMP proteins, these processes may contribute to a vicious cycle of increasing ECM degradation during disease development. 
546 |a EN 
690 |a matrix metalloproteinase (MMP) 
690 |a extracellular matrix 
690 |a myeloperoxidase 
690 |a hypochlorous acid 
690 |a chloramines 
690 |a tissue inhibitor of matrix metalloproteinase (TIMP) 
690 |a Therapeutics. Pharmacology 
690 |a RM1-950 
655 7 |a article  |2 local 
786 0 |n Antioxidants, Vol 11, Iss 8, p 1616 (2022) 
787 0 |n https://www.mdpi.com/2076-3921/11/8/1616 
787 0 |n https://doaj.org/toc/2076-3921 
856 4 1 |u https://doaj.org/article/5d7fc843b0ab43f08fde4b35b0ad0ea9  |z Connect to this object online.